Fidanacogene elaparvovec
PreclinicalGene therapy
PfizerFidanacogene elaparvovec is a gene therapy that works as a Factor IX Gene Therapy.[1] It is being investigated across 1 indication, with its most advanced program in Preclinical.
Fidanacogene elaparvovec is one of 20 gene therapy programs targeting Hemophilia B. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[2]
Indication
Competition
Competitive Landscape
42 competitors in Hemophilia B
#DrugCompanyPhaseTrials
1Recombinant Factor IX Coagulation
PfizerApproved
IB1001
MMedexus Pharma, Inc.
Phase 3
Translarna
PPTC Therapeutics
Phase 2
BENEFIX
PfizerPhase 3
Recombinant Factor IX
BBaxalta now part of Shire
Phase 3
Rfix
PfizerPhase 3
Factor Ix
CSL BehringPhase 3
Rix-FP
CSL BehringPhase 3
Nonacog Alfa
PfizerPhase 3
Rfixfc
BBioverativ Therapeutics Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources